PTC Therapeutics (PTCT) pipeline and stated timing

Name in SEC filings: PTC THERAPEUTICS, INC.

Pipeline at a glance

Program	Event	Stage	Stated timing	Filing
vatiquinone	submission	—	in December 2024	10-Q · Nov 7, 2024
ST-920	NDA/BLA submission	—	in 2026	8-K · Sep 21, 2026

Source: ORION, orionbiotechai.com/company/PTCT, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/PTCT

Nearest upcoming stated timing: ST-920 · NDA/BLA submission · in Q4 2026

SEC sources last checked Oct 18, 2026.

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

vatiquinone

Friedreich ataxia

Matched

NDA/BLA submissionin December 2024

Stage: —

Public float: $3,350,589,128 · as of Jun 30, 2025 · SEC filing

The Company plans to submit an NDA for vatiquinone for the treatment of FA in the United States in December 2024.

10-Q · Filed Nov 7, 2024 · Last checked Oct 18, 2026

Source details

Accession 0001070081-24-000023

Resolution filing: Jul 30, 2026 · SEC filing

Alert me · Calendar: same stage and window-end month (2024-12)

ST-920

Fabry disease

Matched

NDA/BLA submissionin Q4 2026

Stage: —

Public float: $3,350,589,128 · as of Jun 30, 2025 · SEC filing

A rolling BLA submission to FDA for accelerated approval of ST-920 is expected to be completed in Q4 2026.

8-K · Filed Sep 21, 2026 · Last checked Oct 18, 2026

Source details

Accession 0001070081-26-000023

Alert me · Calendar: same stage and window-end month (2026-12)

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of Oct 19, 2026.

Program / event	Stated period and SEC wording	Disclosure in stated period
ST-920Submission	in Q4 2026 “A rolling BLA submission to FDA for accelerated approval of ST-920 is expected to be completed in Q4 2026.” Filed Sep 21, 2026 · EX-99.1	Still within period As of Oct 19, 2026
ST-920Submission	in the fourth quarter of 2026 “a rolling biologics license application (“BLA”) submission to the U.S. Food and Drug Administration for accelerated approval of ST-920 is expected to be completed in the fourth quarter of 2026.” Filed Sep 21, 2026 · 8-K	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.
ST-920Submission	in Q4 2026 “A rolling BLA submission to FDA for accelerated approval of ST-920 is expected to be completed in Q4 2026.” Filed Aug 13, 2026 · EX-99.1	Still within period As of Oct 19, 2026
ST-920Submission	in the fourth quarter of 2026 “A rolling biologics license application (“BLA”) submission to FDA for accelerated approval of ST-920 is expected to be completed in the fourth quarter of 2026.” Filed Aug 13, 2026 · 8-K	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.
vatiquinoneSubmission	in December 2024 “The Company plans to submit an NDA for vatiquinone for the treatment of FA in the United States in December 2024.” Filed Nov 7, 2024 · 10-Q	Not compared The stated period has ended. ORION has no record of a complete search of SEC filings from that period.
vatiquinoneSubmission	in December 2024 “We plan to submit an NDA for vatiquinone for the treatment of FA in the United States in December 2024.” Filed Nov 7, 2024 · 10-Q	Not compared The stated period has ended. ORION has no record of a complete search of SEC filings from that period.
vatiquinoneSubmission	in December 2024 “PTC plans to submit an NDA for vatiquinone for the treatment of Friedreich ataxia in December 2024.” Filed Nov 7, 2024 · EX-99.1	Not compared The stated period has ended. ORION has no record of a complete search of SEC filings from that period.

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Retained company announcements

Historical summaries and source dates are retained separately from the SEC timing quotes above. Earlier publications were collected retrospectively.

Historical catalog checked Sep 26, 2026.

No historical announcement trail is retained for this company in this catalog.

Selected registry record

Sepiapterin · NCT06302348

Condition in the selected registry record: Phenylketonuria
Phase in the selected registry record: Phase 3
Identity checked: Sep 26, 2026

Original ClinicalTrials.gov record · Open the selected study

Retained company–study identity sources

Scope of retained company and registry evidence

These are selected linked records and dated source metadata, not a live registry recheck or the company’s full pipeline. Company announcements and the selected registry study are separate evidence sets. No stage or event timing is borrowed between them.

Coverage and identity checks

Watch PTCT

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for PTCT. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window: The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date: The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q: First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original: The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status: One of seven labels set by founder review of the original filings. Definitions: Methodology.

See PTCT in the calendar · Review labels and methodology